Teclistamab (Code C136823) |
Terms & Properties |
Preferred Name: Teclistamab
Definition: A bispecific humanized monoclonal antibody against human CD3, a T-cell surface antigen, and human B-cell maturation antigen (BCMA; TNFRSF17), a tumor-associated antigen (TAA) expressed on plasma cells, with potential antineoplastic activity. Upon administration, teclistamab binds to both CD3 on T-cells and BCMA expressed on malignant plasma cells. This results in the cross-linking of T-cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against BCMA-expressing plasma cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.
Display Name: Teclistamab
Label: Teclistamab
NCI Thesaurus Code: C136823 (Search for linked caDSR metadata) (search value sets)
NCI Metathesaurus Link: CL524654 (see NCI Metathesaurus info)
Synonyms & Abbreviations: (see Synonym Details)
JNJ 64007957 |
JNJ-64007957 |
JNJ64007957 |
Teclistamab |
TECLISTAMAB |
Teclistamab-cqyv |
Tecvayli |
External Source Codes:
CAS Registry Number | 2119595-80-9 (see NLM ChemIDplus info) |
NCI Drug Dictionary ID | 789710 (see NCI Drug Dictionary info) |
FDA UNII Code | 54534MX6Z9 |
PDQ Closed Trial Search ID | 789710 |
PDQ Open Trial Search ID | 789710 |
NCI META CUI | CL524654 |
Other Properties:
Name | Value (qualifiers indented underneath) | ||||
---|---|---|---|---|---|
code | C136823 | ||||
Contributing_Source | CTRP | ||||
Contributing_Source | FDA | ||||
Contributing_Source | GDC | ||||
Contributing_Source | HemOnc | ||||
Maps_To | Anti-CD3/Anti-BCMA Bispecific Monoclonal Antibody JNJ-64007957 | ||||
|
|||||
Maps_To | Teclistamab | ||||
|
|||||
Semantic_Type | Pharmacologic Substance |
Additional Concept Data:
Defined Fully by Roles: No |
URL:https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C136823 |